Lung clearance of inhaled 99tcm-erythromycin lactobionate in non-smokers and smokers

Nuclear Medicine Communications

Volumn 17, Issue 10, 1996, Pages 895-901

  Durak, Hatice ^a   Sayit, E ^a   Degirmenci B ^a   Yurekli Y ^a   Ertay, T ^a   Guven H ^a   Aktogu S ^b  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b Department of Chest Diseases   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN LACTOBIONATE; PENTETATE TECHNETIUM TC 99M; TECHNETIUM 99M; XENON 133;

ADULT; AEROSOL; ARTICLE; CASE REPORT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; LUNG CLEARANCE; LUNG EMBOLISM; LUNG SCINTISCANNING; LUNG VENTILATION; MALE; SMOKING;

EID: 0029824920     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199610000-00012     Document Type: Article

References (41)

1. Lee Hand W, King Thompson NL, Steinberg TH. Interactions of antibiotics and phagocytes. J Antimicrob Chemother 1983; 12 (suppl. C): 1-11.
2. Lee Hand W, Corwin RW, Steinberg TH, Grossman GD. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis 1984; 129: 933-937.
3. Carre P, Piva F, Aerts C, Voisin C, Wallaert B. Etude de la penetration in vivo de l’erythromycine dans les macrophages alveolaires. Rev Mai Resp 1990; 7: 110-122.
4. m Erythromycin lactobionate in rabbits. Nucl Med Biol 1996; 23: 291-293.
5. Pillay M, Akkermans JA, Cox PH. A high efficiency ultrasound nebuliser for radioaerosol studies of the lungs. Eur J Nucl Med 1987; 13: 331-334.
6. Peltier P, Chatal JF. 99mTc-DTPA and 99mTc-rhenium sulfur aerosol compared as adjuncts to perfusion scintigraphy in patients with suspected pulmonary embolism. Eur J Nucl Med 1986; 12: 254-257.
7. Ijitman AT, Collier BD, Palmer DW et al. Comparison of technetium-99m pyrophosphate and technetium-99m DTPA aerosols for SPECT ventilation lung imaging. J Nucl Med 1988; 29: 1761-1767.
8. Miron SD, Wiesen EJ, Feiglin DH, Cohen AM, Bellon EM. Generation of parametric images during routine Tc-99m PYP inhalation/Tc-99m MAA perfusion lung scintigraphy: Technical note. Clin Nucl Med 1991; 16: 501-505.
9. Işitman AT, Manoli R, Schmidt GH, Holmes RA. An assessment of alveolar deposition and pulmonary clearance of radiopharmaceuticals after nebulization. Am J Roentgenol 1974; 120: 776-781.
10. Peltier P, Bardies M, Chetanneau A, Chatal JF. Comparison of technetium-99m and phytate aerosol in ventilation studies. Eur J Nucl Med 1992; 19: 349-354.
11. Thomas SH, O’Doherty MJ, Page CJ, Nunan TO. Variability in the measurement of nebulized aerosol deposition in man. Clin Sci 1991; 81: 767-775.
12. Nilsson K, Wollmer P. Pulmonary clearance of 99mTc-DTPA and 99mTc-albumin in rabbits with surfactant dysfunction and lung injury. Clin Physiol 1992; 12: 587-594.
13. Nilsson K, Wollmer P. Pulmonary clearance of tracers with different lipid and water solubility in experimental surfactant dysfunction. Eur Respir J 1993; 6: 505-508.
14. Ercan MT, Ulutuncel N, Naldoken S. Evaluation of Tc 99m labelled a-D-glucose-1-phosphate aerosols for SPECT ventilation lung imaging. Nucl Med Commun 1993; 14: 433-438.
15. Burch WM, Tetley IJ, Gras JL. Technetium 99m 'pseudogas' for diagnostic studies in the lung. Clin Phys Physiol Meas 1984; 5: 79-85.
16. Logus JW, Jette DC, Mau SF. An improved method of sulphur colloid radioaerosol inhalation. J Nucl Med Technol 1983; 11: 137-139.
17. Laube BL, Links JM, Wagner HN et al. Simplified assessment of fine aerosol distribution in human airways. J Nucl Med 1988; 29: 1057-1065.
18. Peltier P, De Faucal P, Chetanneau A, Chatal JF. Comparison of technetium-99m aerosol and krypton-81m in ventilation studies for the diagnosis of pulmonary embolism. Nucl Med Commun 1990; 11: 631-638.
19. Isawa T, Teshima T, Anazawa Y, Miki M, Motomiya M. Technegas for inhalation lung imaging. Nucl Med Commun 1991; 12: 47-55.
20. Crawford AB, Davison A, Amis TC, Engel LA. Intrapulmo-nary distribution of 99m technetium labelled ultrafine carbon aerosol (Technegas) in severe airflow obstruction. Eur Respir J 1990; 3: 686-692.
21. Amis TC, Crawford AB, Davison A, Engel LA. Distribution of inhaled 99mTechnetium labelled ultrafine carbon particle aerosol (Technegas) in human lungs. Eur Respir J 1990; 3: 679-685.
22. Cook G, Clarke SE. An evaluation of Technegas as a ventilation agent compared with krypton-81 m in the scintigraphic diagnosis of pulmonary embolism. Eur J Nucl Med 1992; 19: 770-774.
23. Scalzetti EM, Grossman ZD, Gagne GM. Experimentally produced pulmonary arterial occlusion in the dog: Identification with pertechnegas inhalation. Radiology 1993; 186: 423-426.
24. Kennedy SM, Walker DC, Belzbierg AS, Hogg JC. Macrophage accumulation of inhaled gallium-67 citrate in normal lungs. J Nucl Med 1985; 26: 1195-1201.
25. Kawakami K, Tominaga S, Takagi H et al. Pulmonary clearance of 99mTc-HMPAO aerosol. Kaku Igaku 1990; 27: 451-457.
26. Keegan J, Bailey J, Wilkinson P, Davies S, Rudd R. Regional lung microvascular permeability using dual isotope scintigraphy. Nucl Med Commun 1989; 10: 871-878.
27. Huchon GJ, Montgomery AB, Lipavsky A, Hoeffel JM, Murray JF. Pulmonary clearance of three aerosolized solutes in oleic acid-induced lung injury. J Appl Physiol 1988; 64: 1171-1178.
28. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Davies ER, Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994; 88: 203-211.
29. Huchon GJ, Montgomery AB, Lipavsky A et al. Respiratory clearance of aerosolized radioactive solutes of varying molecular weight. J Nucl Med 1987; 28: 894-904.
30. Lazarus C. Radiopharmaceuticals. In: Maisey MN, Britton KE, Gilday DL, eds. Clinical nuclear medicine. Philadelphia, PA: J.B. Lippincott, 1991: 518-519.
31. Beyer J, Barzen G, Risse G et al. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1993; 37: 1967-1969.
32. Garratt DC. The quantitative analysis of drugs. London: Chapman and Hall, 1964: 73-74.
33. Krasnow AZ, Işitman AT, Collier BD. Diagnostic applications of radioaerosols in nuclear medicine. In: Freeman LM, ed. Nuclear medicine annual 1993. New York: Raven Press, 1993: 123-193.
34. Byron PR. Respiratory drug delivery. Boca Raton, FL: CRC Press, 1990.
35. Lee Hand W, Boozer RM, King Thompson NL. Antibiotic uptake by alveolar macrophages of smokers. Antimicrob Agents Chemother 1985; 27: 42-45.
36. Cherniack RM. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis and selected comparison groups. Am Rev Respir Dis 1990; 141 (5, part 2, suppl): S177.
37. Riyami BMS, Kinsella J, Pollok AJ et al. Alveolar macrophage chemotaxis in fire victims with smoke inhalation and burns injury. Eur J Clin Invest 1991; 21: 485-489.
38. van de Flierdt E, Bauer R, Laubenbacher C, Didic M, Lang-hammer HR, Pabst HW. Fruherkennung von morphologisch-funktionellen Veränderungen der Atemwege durch eine einfache Methode der Inhalationsszintigraphie. Nuklearmedizin 1992; 31: 7-15.
39. Köhler D, Coates G, Dolovich M, Newhouse M, Matthys H. Ventilationsszintigraphie der lunge mit 99m Tc-DTPA oder mit 99mTc-Schwefelkolloid? Nuklearmedizin 1983; 12: 115-119.
40. O'Doherty MJ, Page CJ, Croft DN, Bateman NT. Regional lung epithelial leakiness in smokers and nonsmokers. Nucl Med Commun 1985; 6: 353-357.
41. Kennedy SM, Walker DC, Belzbierg AS, Hogg JC. Macrophage accumulation of inhaled gallium-67 citrate in normal lungs. J Nucl Med 1985; 26: 1195-1201.